Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
Authors:
- Keaven M AndersonKAKeaven M Anderson
- Robert M CaliffRCRobert M Califf
- Gregg W StoneGSGregg W Stone
- Franz-Josef NeumannFNFranz-Josef Neumann
- Gilles MontalescotGMGilles Montalescot
- Dave P MillerDMDave P Miller
- James J FergusonJFJames J Ferguson
- James T WillersonJWJames T Willerson
- Harlan F WeismanHWHarlan F Weisman
- Eric J TopolETEric J Topol
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial InfarctionNew England Journal of Medicine, 2001
- Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarctionJACC, 2000
- Acute Platelet Inhibition With Abciximab Does Not Reduce In-Stent Restenosis (ERASER Study)Circulation, 1999
- Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 1998
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Myonecrosis After Revascularization ProceduresJACC, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.Circulation, 1994